Therapeutic options in the management of renal cell carcinoma

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 7, 2002, Pages 41-46

  Glaspy, John A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; COLCHICINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HISTAMINE; INTERLEUKIN 2; OXALIPLATIN; TAMOXIFEN; VINBLASTINE;

ANGIOGENESIS; ANTIGEN EXPRESSION; CLINICAL TRIAL; HUMAN; KIDNEY CARCINOMA; METASTASIS; MULTIDRUG RESISTANCE; NATURAL KILLER CELL; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T LYMPHOCYTE; TUMOR GROWTH;

EID: 0036269257     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.33083     Document Type: Article

References (44)

1. Cancer statistics, 1999
2. Renal cell carcinoma: Recent progress and future directions
3. The results of radical nephrectomy for renal cell carcinoma
4. Contemporary management of renal cell carcinoma with coexistent renal artery disease: Update of the Cleveland Clinic experience
5. Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria
6. Proceedings: Carcinoma of the kidney
7. Postoperative radiotherapy in stage II and III renal adenocarcinoma: A randomized trial by the Copenhagen Renal Cancer Study Group
8. Combination chemotherapy, of advanced renal cell cancer with CCNU and vinblastine
9. Response of renal adenocarcinoma to cyclophosphamide
10. Chemo-hormonal therapy for metastatic renal cell carcinoma with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate
11. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
12. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial
13. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial
14. Kidney and ureter
15. Renal cell carcinoma: Long-term survival and late recurrence
16. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases
17. Cytoreductive surgery in the management of metastatic renal cell carcinoma: The UCLA experience
18. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma
19. Prognostic factors in metastatic renal carcinoma
20. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
21. Chemotherapy for advanced renal cell carcinoma, 1983-1993
22. Systemic therapy for renal cell carcinoma
23. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer
24. Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: A phase II study
25. Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma: Results of a pilot study
26. The treatment of renal cell carcinoma with human leukocyte alpha-interferon
27. Phase II study of interferon alpha in metastatic renal-cell carcinoma: A progress report
28. Interferon therapy for renal cell carcinoma
29. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: High response rate in patients with pulmonary metastases
30. Cytokine therapy for metastatic renal cell carcinoma
31. Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer
32. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma
33. Immunotherapy for metastatic renal cell carcinoma
34. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
35. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
36. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe
37. Home therapy with recombinant interleukin-2 and interferon-α 2b in advanced human malignancies
38. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma
39. Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients
40. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma
41. Histamine in immunotherapy of advanced melanoma: A pilot study
42. UH: Histamine in cancer immunotherapy
43. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma
44. Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: Results of an open, single-armed, multi-center phase-II study